Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader

13 Dec 2024

Abstract excerpt

Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer. However, continual evolution during prostate cancer progression can result in AR alterations (e.g., mutation, amplification, and splicing)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39670468
DOI: 10.1158/1535-7163.mct-23-0655

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor DegraderPMID 39670468Read ↗

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerSemantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degraderSemantic proximity Read ↗

An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerSemantic proximity Read ↗

PROTACs in the Management of Prostate Cancer.Semantic proximity Read ↗

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor DegradationSemantic proximity Read ↗

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.Semantic proximity Read ↗

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.Semantic proximity Read ↗

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read ↗

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerSemantic proximity Read ↗

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.